Finding who is at high risk for inflammatory bowel disease
SNU IBD Cohort Study : Searching for Characterization of High Risk Populations for Developing Inflammatory Bowel Disease (SNU PREVENT)
This project will see if clinical features, blood markers, genetics, and the gut microbiome can predict who will develop IBD among people at higher risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 500 (estimated) |
| Ages | 10 Years and up |
| Sex | All |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul) |
| Trial ID | NCT07011979 on ClinicalTrials.gov |
What this trial studies
Researchers will follow people at higher risk for IBD—including first-degree relatives, patients with certain autoimmune diseases, and ASCA-positive functional GI patients—and compare them with healthy and IBD populations. Participants will provide demographic and clinical information, complete symptom questionnaires at regular intervals, and give blood and stool samples for genomic, proteomic, metabolomic, and microbiome (16S and whole genome shotgun) analyses. When clinical colonoscopy occurs, biopsy tissue will be collected for proteomic study, and adverse events related to blood sampling will be monitored in the outpatient clinic. The goal is to identify patterns of risk factors that precede IBD onset.
Who should consider this trial
Good fit: Ideal participants are first-degree relatives of IBD patients, people diagnosed with autoimmune diseases, and patients with functional gastrointestinal disorders who are ASCA-positive but do not have diagnosed IBD.
Not a fit: People who already have symptomatic or confirmed IBD or who have excluded conditions such as diabetes mellitus, irritable bowel syndrome, or colon cancer are not expected to benefit from this protocol.
Why it matters
Potential benefit: If successful, this work could enable earlier identification and closer monitoring of people at high risk for developing IBD.
How similar studies have performed: Previous cohort and microbiome studies have identified genetic and microbial associations with IBD risk, but prospective multi-omics follow-up in high-risk relatives is less commonly performed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * first-degree relatives of Inflammatory Bowel Disease patients * patients who are diagnosed with autoimmune diseases * patients with functional gastrointestinal disorders who are ASCA-positive Exclusion Criteria: * Patients with symptoms such as a 10% weight loss within 3 months, abdominal pain, hematochezia, or diarrhea will undergo colonoscopy, and those diagnosed with Inflammatory Bowel Disease will be excluded. * Treatment history of Diabetes Mellitus, Irritable Bowel Syndrome, or colon cancer.
Where this trial is running
Seoul
- Seoul National University Hospital — Seoul, South Korea (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.